Akeso's ivonescimab grabbed a coveted Plenary Session slot at ASCO 2026 with overall survival data from the HARMONi-6 trial in advanced squamous NSCLC.
Chinese biotech companies presented nearly double the number of abstracts at ASCO 2026 compared with 2024, signaling China's arrival as a major innovation hub in oncology.
Ivonescimab is a PD‑1/VEGF bispecific antibody developed by Akeso; it is approved in China and under U.S. regulatory review for EGFR‑mutated lung cancer.
Akeso showcased more than 40 clinical studies across bispecifics such as cadonilimab (PD‑1/CTLA‑4) and ivonescimab, underscoring China’s growing depth in next‑generation antibody platforms.
Analysts frame this surge as a turning point, with China now challenging decades of U.S. dominance in global oncology drug development.
Sources:
Akeso, Summit drug extends survival in closely watched lung cancer ...
Summit's PD-1/VEGF to take center stage at ASCO, with wide impact ...
Welcome to the 2026 ASCO Annual Meeting - Moffitt Cancer Center
ASCO 2026: Experts Preview Practice-Shifting Studies
American Society of Clinical Oncology® (ASCO) Annual Meeting 2026
ASCO 2026 | Congress Essentials | BeOne Medical Affairs
China's Biotech Surge at ASCO 2026 Challenges US Dominance
Over 40 Studies Featuring Akeso's Innovative Oncology ...
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to ...
As Akeso takes center stage at ASCO, China biotech industry ...
All eyes on Revolution, bispecific antibodies and more at ASCO26
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to ...
ASCO 2026: Chinese ADCs make a powerful statement with first ...
What does Akeso's primo plenary spot say about its survival data?